Navigation Links
Stemedica International Announces Joint Venture with AnC Bio Group
Date:10/5/2010

SAN DIEGO, Oct. 5 /PRNewswire/ -- Stemedica International, S.A., ("Stemedica"), a wholly owned subsidiary of Stemedica Cell Technologies, Inc., announced the signing of an agreement to form a joint venture with AnC Bio, a global manufacturer of stem cell-based products.  The new venture, StemedicaAnC, will manufacture stem cells developed by Stemedica for the treatment of ischemic stroke and other degenerative disorders.  The initial manufacturing capacity of this alliance will produce enough products to meet the Company's five-year revenue projections, with an expansion capacity to manufacture multiple stem cell products to meet the anticipated long-term growth of the international market for stem cells.  

AnC's biomanufacturing facility was built at an estimated cost of 120 million dollars over a five year period.  "The synergy between Stemedica's technology and AnC's technically advanced manufacturing facility positions StemedicaAnC as the global leader in stem cell production," said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer.  "The facility will provide StemedicaAnC with the capacity to manufacture its multiple allogeneic stem cell products to meet international safety and quality standards established by the United States FDA, Swissmedic, the European regulatory agency and Korea's FDA."

"We are pleased to be working with Stemedica to accelerate the advancement of stem cell therapy," said Alex Choi, Chairman and Chief Executive Officer of the AnC Bio Group.  "This joint venture will provide stem cell products to institutions around the world that are conducting clinical trials and stem cell research."

"We have invested significant time and effort in our search for a best-in-class stem cell manufacturing facility to accommodate our technology," said Roger J. Howe, PhD, Executive Chairman of Stemedica.  "AnC Bio provides an excellent fit for our international business development strategy."

"This is an exciting time for both companies," said Ike W. Lee, PhD, President and Chief Technology Officer of AnC Bio.  "Stemedica's advanced technology and operating systems will be a significant addition to AnC Bio's manufacturing facility.  I am looking forward to working with their team of scientists and engineers."

The joint venture will be overseen by a Board of Directors representing both Stemedica and AnC Bio.  Planning for operations is expected to begin by year end.

About Stemedica Cell Technologies, Inc.Stemedica Cell Technologies, Inc. (www.stemedica.com) is a specialty biopharmaceutical company that develops and manufactures best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials.  The company is currently developing regulatory pathways for neurology, cardiology, ophthalmology, wound care and dermatology. Stemedica is headquartered in San Diego, California.  For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan@stemedica.com

About AnC Bio GroupAnC Bio Group is a Korean Corporation with three operating divisions: the cell therapy division which includes a state-of-the-art cell culture cGMP facility; the artificial organs division that designs, manufactures and distributes artificial human organs such as kidney dialysis and artificial combined heart and lung machines; and the vaccine division that develops, manufactures and distributes various kinds of cell culture-based vaccines including influenza, avian, Alzheimer's and anthrax. For more information regarding AnC Bio, please visit www.ancbio.com. Media contact:Dave McGuiganStemedica Cell Technologies Inc.+18586580910dmcguigan@stemedica.comhttp://www.stemedica.com
'/>"/>

SOURCE Stemedica International, S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
2. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
3. Stemedica Requests Pre-IND Meeting With FDA
4. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
5. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
6. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
7. International Robotic Urology Symposium 2011
8. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
9. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
10. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
11. Webmedx and NLP International Team to Bring Natural Language Processing Software to Medical Transcription
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... preferred physical therapy provider for Derby City CrossFit, effective immediately. , In addition ... quickly and effectively as possible, ProRehab’s sports physical therapists will work with athletes ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
Breaking Medicine News(10 mins):